Trial Profile

A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO (REGISTERED)) IN COMBINATION WITH AXITINIB (INLYTA (REGISTERED)) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER OR TREATMENT NAIVE CISPLATIN-INELIGIBLE UROTHELIAL CANCER JAVELIN MEDLEY VEGF

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Axitinib (Primary)
Indications Bladder cancer; Carcinoma; Non-small cell lung cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms Javelin Medley VEGF
Sponsors Pfizer

03 May 2023 This trial has been completed in Poland (End Date: 09 Feb 2023), according to European Clinical Trials Database record.
22 Mar 2023 Status changed from active, no longer recruiting to discontinued.
02 Feb 2023 Planned End Date changed from 28 Dec 2022 to 14 Feb 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com